EC
LEGN icon

Elmind Capital’s Legend Biotech LEGN Stock Holding History

Elmind Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Buy
+570,569
New +$15.4M 4.14% 11

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Elmind Capital's LEGN Position: Q2 2026 in Review

Elmind Capital opened a new position in Legend Biotech (LEGN) in Q2 2026: 570,569 shares worth $16.5M. The stake represents 4.14% of the portfolio and ranks #11 among its holdings.

218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Elmind Capital held 570,569 shares of Legend Biotech worth $16.5M as of Q2 2026.
  • Legend Biotech was a new Elmind Capital position in Q2 2026.
  • Legend Biotech made up 4.14% of Elmind Capital's portfolio in Q2 2026, its #11 holding.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.